Rahul K. Verma, PhD

Department of Science and Technology
Office- Room-15
Institute of Nano Science and Technology Habitat Centre
Phase- 10, Sector- 64
Mohali, Punjab-160062, India



Dr. Verma is a Scientist at Institute of Nano Science and Technology (INST), a premier autonomous institute of Department of Science and Technology (DST), Government of India. He received his PhD from Central drug Research Institute (CDRI), Lucknow, India and MS from the National Institute of Pharmaceutical Education and Research (NIPER), Mohali, both in Pharmaceutical sciences. He performed postdoctoral research at University of Oklahoma, USA. Dr. Verma also worked as Visiting Researcher sponsored by Royal Society of United Kingdom, at Bradford University, Bradford, United Kingdom. He is a recipient of the CDRI incentive award and two times recipient of BRG-France travel award. Dr. Verma has published several research papers and book sections in highly reputed International Journals and books respectively.

Research Interest

His current research interests include: Engineered aerosol biomaterials for controlled delivery of drugs, peptides, and vaccines, Nanoscale manipulation of multiphase polymeric materials, Bio-inspired materials, Nanoparticles etc. It mainly involves designing, development and evaluation of polymeric inhalable particulate drug delivery systems (microparticles, Nanoparticles, Porous Nanoparticle Aggregates (PNAP)) for Pulmonary & Nasal administration. He is an expert in formulation development using spray drying, Spray freeze drying, supercritical fluid technology and microfluizider. In addition he conducted research in preclinical Pharmacokinetic, therapeutic and toxicological evaluation in cells lines and animal models.

Scientific Activities


• CSIR, INDIA-Royal Society of United Kingdom Fellowship UK-2009-2010-received to work in UK at Institute of pharmaceutical Innovation (IPI) Bradford University in year (2009-2010)
• Directors Special CDRI incentive award-2009-received for publication in high impact research journal Antimicrobial Agents and Chemotherapy (AAC) in research in year (2008)
• BRG-France travel Award- received to travel and present at Groningen University, THE NETHERLANDS in (2009)
• BRG-France travel Award- received to travel and present at Dublin City University, Dublin, IRELAND in (2008)
• CSIR-SRF-Qualified Senior Research Fellowship-2009 (Council of Scientific & Industrial Research (CSIR), INDIA
• CSIR-NET-LS -Qualified Lecturership (LS)-2005, National Eligibility test for Lecturership in Indian Universities
• GATE (Graduate Aptitude Test for Engineering) – Qualified in Pharmaceutical Sciences –(2004) organized by Indian Institute of Technology (IIT), INDIA
• NIPER-Fellowship-Qualified to pursue M.S. (Pharm.) at National Institute of Pharmaceutical Education and Research (NIPER), Mohali, INDIA (2003)


1. Ibrahim M, Verma RK, Garcia-Contreras L. Inhalation drug delivery devices: technology update (8). Medical devices-evidence and research. 2015; 131-139.
2. Verma RK, Garcia-Contreras L. In Vitro Comparison of Two Nasal Delivery Devices to Administer Dry Powders. Respiratory Drug Delivery (RDD). 2014; 156-161.
3. Verma RK, Germishuizen WA, Motheo MP, et al. Inhaled microparticles containing clofazimine are efficacious in the treatment of experimental tuberculosis in mice. Antimicrobial Agents and Chemotherapy (AAC). 2013; 57(2): 1050-1052. doi: 10.1128/AAC.01897-12
4. Verma RK, Singh AK, Mohan M, et al. Inhalable Microparticles Containing Nitric Oxide Donors: Saying NO to Intracellular Mycobacterium Tuberculosis. Molecular Pharmaceutics (Mol. Pharm). 2012; 9(11): 3183-3187. doi: 10.1021/mp300269g
5. Verma RK, Mukker JK, Singh RSP, Kumar K, Verma PRP, Misra A. Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to Rhesus macaques. Molecular Pharmaceutics (Mol. Pharm). 2012; 9(4): 1011-1016. doi: 10.1021/mp300043f
6. Verma RK, Agrawal AK, Singh AK, et al. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium. Tuberculosis. 2013; 93(4): 412-417. doi: 10.1016/j.tube.2013.02.012
7. Verma RK, Kaur J, Kumar K, Yadav AB, Misra A. Intracellular time course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary delivery of inhalable Microparticles to Mice. Antimicrobial Agents and Chemotherapy (AAC). 2008; 52(9): 3195-3201. doi: 10.1128/AAC.00153-08
8. Verma RK, Pandya S, Misra A. Loading and Release of Amphotericin-B from Biodegradable Poly (lactic-co-glycolic acid) Nanoparticles. Journal Biomedical Nanotechnology (JBN). 2011; 7: 118-120. doi: 10.1166/jbn.2011.1230
9. Verma RK, Singh AK, Mohan M, Agrawal AK, Misra A. inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug delivery systems. Therapeutic Delivery (Ther Delv.). 2011; 2(6): 753-768.
10. Verma RK, Tripathy RK, Paul MK, Nayyar A, Jain R, Mukhopadhayay AK. Bacterial DNA gyrase is not the target of quinoline based anti-tubercular compounds. International Research journal of Pharmacy(IJRP). 2013; 4(1): 284-292.
11. Singodia D, Verma A, Verma RK, Mishra PR. Investigations on Alternate Approach to Target Mannose Receptors on Macrophages using 4-Sulfated N-Acetyl Galactosamine more Efficiently as Compared to Mannose Decorated Liposomes : An Application in Drug Delivery. Nanomedicine-Nanotechnology, Biology and Medicine. 2012; 8(4): 468-477. doi: 10.1016/j.nano.2011.07.002
12. Pandya S, Verma RK, Misra A. Nanoparticles Containing Nitric Oxide Donor with Antileishmanial Agent for Synergistic Effect Against Visceral Leishmaniasis. Journal Biomedical Nanotechnology (JBN). 2011; 7: 213-215.
13. Dwivedi P, Kansal S, Sharma M, et al. Exploiting 4-sulphate N-acetyl galactosamine decorated gelatin nanoparticles for effective targeting to professional phagocytes in vitro and in vivo. Journal of Drug Targeting (JDT). 2012; 20(10): 883-896. doi: 10.3109/1061186X.2012.725169
14. Kansal S,Tandon R, Verma A, et al. Surface coating of doxorubicin loaded nanocapsule with alginate enhances its therapeutic efficacy through Th1 type immune response in Leishmania donovani infected hamsters. British journal of Pharmacology (BJP).
15. Dubey PK, Singodia D, Verma RK, Vyas SP. RGD modified albumin nanospheres for tumour vasculature targeting. Journal Pharmacy and Pharmacology (JPP). 2011; 63(1): 33-40. doi: 10.1111/j.2042-7158.2010.01180.x
16. Yadav AB, Muttil P, Singh, Verma RK, Mohan M, Misra A. The devils advocacy: When and why inhaled therapies for tuberculosis may not work. Tuberculosis. 2010; 9, 65-66. doi: 10.1016/j.tube.2010.10.001
17. Kaur J, Muttil P, Verma RK, et al. Apparatus for Pulmonary Delivery of Microparticles as a Dry Powder Inhalation Targeting Lung and Airway Macrophages in Mice. European Journal of Pharmaceutical sciences (EJPS). 2008; 34: 56-65.
18. Yadav AB, Muttil P, Singh AK, Verma RK, Mohan M, Sinha SK, Misra A. Microparticles induce variable levels of activation in macrophages infected with Mycobacterium tuberculosis. Tuberculosis. 2010; 90: 188-196. doi: 10.1016/j.tube.2010.03.001
19. Yadav AB, Sharma R, Muttil P, Singh AK, Verma RK, Mohan M, Patel SK, Misra A. Inhalable Microparticles Containing Isoniazid and Rifabutin Target Macrophages and Stimulate the Phagocyte to Achieve High Efficacy. Indian journal of Experimental Biology (IJEB). 2009; 469-474.